profit from every $100 of sales.
$0$100
Clene
$3.92-2.00% today
-46.3% in 1 year
1-year low $3.101-year high $10.36
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Clene sold, what it kept, and what it did with the cash.
Sales went from $473,000 in 2022 to $200,000 in 2025, with -$26.2 million of profit last year.
SalesProfit
Clene vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Clene | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Clene's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 1 | 0 | 0 | |
| 0 | 1 | 0 | 0 | |
| -45 | -38 | -32 | -22 | |
| -26 | -43 | -34 | -22 | |
| -30 | -50 | -39 | -26 | |
| -9.20 | -9.43 | -5.67 | -2.65 | |
| 94.5% | 81.5% | 79.5% | 78.5% | |
| -9,420.1% | -5,850.2% | -9,349.4% | -10,908.0% | |
| -6,325.2% | -7,569.4% | -11,520.5% | -13,086.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 44 | 52 | 27 | 18 |
| Cash | 18 | 29 | 12 | 5 |
| Total debt | 32 | 32 | 21 | 22 |
| Total liabilities | 41 | 39 | 36 | 36 |
| 3 | 13 | -9 | -18 | |
| 3 | 5 | 7 | 10 | |
| -60.0% | -78.0% | -232.9% | -454.7% | |
| -924.3% | -369.7% | 444.8% | 148.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -39 | -30 | -21 | -19 | |
| 5 | 0 | 0 | 0 | |
| -44 | -31 | -21 | -19 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 9 | 9 | 8 | 6 |
Valuation
- –
- –
- –
- -4.1×
- 282.2×
- –
- –
- -32.9%
- -46.4%
- 0.0%
Profitability
- 78.5%
- -10,908.0%
- -13,086.5%
- -17,882.8%
- -118.1%
- -238.1%
- 233.9%
- -154.7%
- -139.4%
- 9,596.3%
Growth
- −24.9%
- –
- +12.9%
- –
- +33.8%
Financial health
- –
- -1.17
- 101.8%
- -7.3×
- 1.94
- 1.93
- 0.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 4%of 908
Bottom 1%of 991
What analysts expect
- Average price target
- $50.00
- Range
- $50.00 – $50.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.69 | -0.64 | −8.4% |
| Mar 12, 2026 | -0.88 | -0.74 | −18.9% |
| Nov 13, 2025 | -0.85 | -0.60 | −41.7% |
| Aug 14, 2025 | -0.78 | -0.49 | −59.2% |
| May 7, 2025 | -0.50 | -1.10 | +54.5% |
| Mar 24, 2025 | -1.67 | -1.21 | −38.0% |
| Nov 13, 2024 | -1.22 | -1.34 | +9.0% |
| Aug 7, 2024 | -1.06 | -1.60 | +33.8% |
News
Clene GAAP EPS of $0.05 beats by $0.48, revenue of $0.06M misses by $0.01MSeeking Alpha · Nov 5, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
27No pass
Philip Fisher
46No pass
Peter Lynch
–Not enough data
Joel Greenblatt
2No pass
Charlie Munger
49No pass
Terry Smith
46No pass
Questions about Clene
Is Clene a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Clene AI analysis
What does Clene do?
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is in Biotechnology.
Does Clene pay a dividend?
No. Clene does not pay a dividend at the moment.
Is Clene stock halal?
No. Clene does not pass our halal screen: its debt is 38% of its market value, at or above the 33% limit. How we check
How has Clene stock done over the past year?
Down 46.3% over the past twelve months, to $3.92. It traded between $3.10 and $10.36 and is 62.2% below its high.
Who are Clene's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Clene's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.